Research
Hormonal
Semaglutide does not significantly increase the risk of hypoglycemia in patients not using concomitant insulin or sulfonylureas, due to its glucose-dependent mechanism of action.
You don't need to worry about your blood sugar dropping dangerously low while taking semaglutide by itself. It works gently with your body's natural processes. However, if you are also taking insulin or sulfonylureas, your risk of low blood sugar increases, so your doctor may lower the dose of those other medications.
StrongRefutesVERY_HIGH confidence
since GLP-1RA mainly lower blood glucose by stimulating glucose-dependent insulin secretion, hypoglycemia is an infrequent problem... In SUSTAIN-6, severe or plasma glucose-confirmed (<56 mg/dl) hypoglycemia occurred in similar rates between patients with semaglutide... and placebo
Why this rating
Supported by large phase 3 trials (SUSTAIN-6, PIONEER-6) and real-world data.
Source
Safety of Semaglutide
Mark M. Smits et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.645563
narrative_review · n=21500Cited 267×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (both oral and subcutaneous formulations) is associated with a high incidence of mild-to-moderate, transient gastrointestinal adverse effects (nausea, vomiting, diarrhea), which are dose-dependent and time-dependent, occurring primarily during the initial 8-12 weeks of treatment.Strong
- Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.Strong
- Semaglutide increases the risk of biliary disease (cholelithiasis), which is a class effect of GLP-1 receptor agonists, likely due to rapid weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →